ReviewHypertension research : official journal of the Japanese Society of Hypertension2022
The first software as medical device of evidence-based hypertension digital therapeutics for clinical practice.
Review in Hypertension research : official journal of the Japanese Society of Hypertension, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Cold-Induced Hypertension as Life-Environment Disease in Winter: Focus on Data From Japan.Hypertension (Dallas, Tex. : 1979) · 2026Review
- Digital therapeutics and mHealth applications in cardiovascular prevention: strongest evidence in hypertension and emerging perspectives in dyslipidemia.Frontiers in digital health · 2026Review
- Digital hypertension - what we need for the high-quality management of hypertension in the new era.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Review
- Does Receiving Information on Clinical Trials Affect Patients' Condition?Journal of clinical medicine research · 2025Article
- The Revolution of Digital Therapeutics (DTx) in the Pharmaceutical Industry and Their Quality Impacts.Cureus · 2024Review
- Hypertension treatment up-date on World Hypertension Day 2024: current status and future prospects in Asia.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Preliminary External Validation Results of the Artificial Intelligence-Based Headache Diagnostic Model: A Multicenter Prospective Observational Study.Life (Basel, Switzerland) · 2024Article
- A prospective pilot trial of the health data monitoring system without educational content for patients with hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Home systolic blood pressure time in therapeutic range and cardiovascular risk: the practitioner-based nationwide J-HOP study extended.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Digital hypertension towards to the anticipation medicine.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Review
- What impacts do the new ESH 2023 guidelines have on the management of hypertension in Japan?Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Mapping Factors That Affect the Uptake of Digital Therapeutics Within Health Systems: Scoping Review.Journal of medical Internet research · 2023Article
- Cardiology in a Digital Age: Opportunities and Challenges for e-Health: A Literature Review.Journal of clinical medicine · 2023Review
- Topics 2023 in Hypertension Research leading to guidelines in Asia.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Medical Telemonitoring for the Management of Hypertension in Older Patients in Japan.International journal of environmental research and public health · 2023Review
- Contemporary Role and Applications of Artificial Intelligence in Dentistry.F1000Research · 2023Review
- Exploring the potential of digital therapeutics: An assessment of progress and promise.Digital healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2021, the open-label randomized HERB-Digital Hypertension 1 (HERB-DH1) trial showed for the first time that hypertension digital therapeutics (a hypertension treatment app) successfully reduced blood pressure (BP) in patients with hypertension. Patients in the digital therapeutics group who used the app and home BP monitoring (HBPM) showed significant and persistent decreases in office, home and ambulatory BP values compared with the control group (who were under physician management using HBPM and lifestyle modifications). The results of the pivotal study led to the first global approval of this app for the treatment of hypertension in Japan in 2022, including medical insurance reimbursement. As a result, this hypertension app is expected to become widely used in the clinical management of all stages of hypertension. The most important remaining research issues include the identification of patients likely to respond to this therapeutic approach and the development of clinical efficacy indices. In addition, guidelines for the appropriate use of hypertension apps in the treatment of hypertension are needed. Next steps include the development and research of digital tools to facilitate the behavioral modifications required to prevent hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.